At Revvity, "impossible†is inspiration, and "can't be done†is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. WALTHAM, Mass.--(BUSINESS WIRE) ...

Core Insights - Revvity Inc. shares declined over 2% despite exceeding third-quarter adjusted earnings expectations and raising the full-year profit outlook [1] Financial Performance - The company reported adjusted earnings of $1.18 per share, surpassing the analyst consensus of $1.14 [2] - Revenue for the quarter was $699 million, aligning closely with expectations of $699.39 million, and reflecting a 2% increase from the prior-year quarter [2] - Organic revenue growth was reported at 1% year-over-year [2] Segment Performance - The Diagnostics division experienced a 3% rise in revenue, totaling $356 million [3] - The Life Sciences segment saw a 1% increase in revenue, reaching $343 million [3] - Both segments reported year-over-year declines in adjusted operating margins [3] Future Outlook - Revvity updated its 2025 revenue forecast to a range of $2.83 billion to $2.88 billion, accounting for foreign exchange adjustments [4] - The company maintained its organic growth outlook of 2–4% [4] - Adjusted earnings guidance was raised to $4.90–$5.00 per share, exceeding the consensus estimate of $4.87 [4]

Core Insights - Revvity, Inc. is a leading provider of health science solutions with a market cap of $10.6 billion, serving healthcare, academia, and government sectors with over 11,000 employees [1] Financial Performance - Revvity is expected to report adjusted earnings of $1.14 per share for Q3, a decrease of 10.9% from $1.28 in the same quarter last year [2] - For the full fiscal year 2025, adjusted EPS is projected to be $4.87, slightly down from $4.90 in 2024, with a forecasted increase to $5.35 in fiscal 2026, representing a 9.9% year-over-year growth [3] Stock Performance - RVTY stock has declined by 25.9% over the past 52 weeks, underperforming the Healthcare Select Sector SPDR Fund's 6.7% decline and the S&P 500 Index's 14.7% gain during the same period [4] - Following the release of better-than-expected Q2 results, Revvity's stock fell by 8.3%, despite a 4.1% year-over-year revenue growth to $720.3 million, which exceeded expectations [5] Guidance and Outlook - The company anticipates continued pressure on its margins and subdued organic revenue growth, leading to a reduction in its full-year organic revenue growth guidance from 3%-5% to 2%-4% [6] - Adjusted EPS guidance has also been lowered from $4.90-$5.00 to $4.85-$4.95, which has affected investor confidence [6]